CD274 and sarcoma: Most importantly, we showed that although PD-L1 expression, MSI, TMB/NB, and HLA-LOH were difficult to use as independent biomarkers for anti-PD-1 therapy in metastatic sarcomas, ITH, monocyte ratio, and interstitial subtypes, and the status of immune related signaling pathways may be related to the efficacy of anti-PD-1 therapy in sarcomas.